Your browser doesn't support javascript.
loading
First-in-human study demonstrating the safety and clinical efficacy of novel anti-IL-17A monoclonal antibody CJM112 in moderate to severe plaque psoriasis.
Kaul, M; Jarvis, P; Rozenberg, I; Kolbinger, F; Di Padova, F; Calonder, C; Espie, P; Rondeau, J M; Cebe, R; Huber, T; Mussmann, R; Aassi, M; Sligh, T S.
Afiliação
  • Kaul M; Novartis Institute for Biomedical Research, Basel, Switzerland.
  • Jarvis P; Novartis Institute for Biomedical Research, Basel, Switzerland.
  • Rozenberg I; Novartis Institute for Biomedical Research, Basel, Switzerland.
  • Kolbinger F; Novartis Institute for Biomedical Research, Basel, Switzerland.
  • Di Padova F; Novartis Institute for Biomedical Research, Basel, Switzerland.
  • Calonder C; Novartis Institute for Biomedical Research, Basel, Switzerland.
  • Espie P; Novartis Institute for Biomedical Research, Basel, Switzerland.
  • Rondeau JM; currently Roche Pharma Research & Early Development, Basel, Switzerland.
  • Cebe R; Novartis Institute for Biomedical Research, Basel, Switzerland.
  • Huber T; Novartis Institute for Biomedical Research, Basel, Switzerland.
  • Mussmann R; Novartis Institute for Biomedical Research, Basel, Switzerland.
  • Aassi M; currently Almirall AG, Barcelona, Spain.
  • Sligh TS; Novartis Institute for Biomedical Research, Basel, Switzerland.
J Eur Acad Dermatol Venereol ; 35(5): 1143-1151, 2021 May.
Article em En | MEDLINE | ID: mdl-33617042
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psoríase / Interleucina-17 Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psoríase / Interleucina-17 Idioma: En Ano de publicação: 2021 Tipo de documento: Article